Validity of mesothelin in occupational medicine practice

30/03/2016
Author:  Petra Smolkova et al

Petra Smolkova et al
International Journal of Occupational Medicine and Environmental Health 2016;29(3)

Objectives

Malignant mesothelioma (MM) is the most serious asbestos-related disease. Its increasing incidence is alarming, suggesting the need for as early diagnosis as possible. This 4.5-year prospective longitudinal study aimed at assessing the benefit of measuring serum mesothelin as a marker for diagnosing malignant mesothelioma in individuals with previous occupational exposure to asbestos, as a part of their clinical follow-up care.

Material and Methods

The study comprised 309 participants (235 males, 74 females) with a mean age of 58.9 years (standard deviation (SD) = 9.8) and a mean duration of exposure to asbestos dust of 13.4 years (SD = 9.3). From 2009 to June 2013, all subjects were followed at a department of occupational medicine in Olomouc. Apart from the standard parts of medical examination (history, physical examination, simple chest radiographs and spirometry), the patients’ serum mesothelin levels were determined by the Mesomark immunoenzymatic diagnostic assay. Statistical analysis of the validity of serum mesothelin level measurement was carried out with respect to the diagnosis of MM.

Results

Among the participants, 16 (5.2%) individuals (14 males and 2 females) were diagnosed with malignant mesothelioma. Based on the detected mesothelin levels, their validity for prediction of malignant mesothelioma was calculated as follows: sensitivity – 0.75, specificity – 0.962, positive predictive value – 0.706, negative predictive value – 0.969, positive and negative likelihood ratios – 19.95 and 0.26, respectively, and diagnostic odds ratio – 76.8, at a 95% confidence interval.

Conclusions

The high specificity was identified indicating the low false positivity as well. In the case of detecting elevated soluble mesothelin-related peptides (SMRP) levels in formerly asbestos-exposed individuals, the possibility of the presence of MM should be included into the clinical consideration. The high negative predictive value denotes a lower probability of the presence of MM in patients with normal SMRP levels but due to the limiting lower sensitivity this possibility cannot be entirely excluded.

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.